You are here: Industry Insights > Interim Results

News List

InnoCare Releases 2024 Interim Results and Business Highlights August 21, 2024
InnoCare Pharma announced the 2024 interim results and corporate update as of 30 June 2024.
InnoCare Pharma announced 2023 interim results as of 30 June 2023 PharmaSources
September 04, 2023
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2023 interim results as of 30 June 2023.
Universal Medical Announces 2021 Interim Results ACN Newswire
September 07, 2021
The board (the "Board") of directors (the "Directors") of Genertec Universal Medical Group Company Limited (the "Company" or "Universal Medical"; Stock code: 2666.HK) is pleased to announce the unaudited interim results of the Company and its subsidiaries
CSPC Pharmaceutical Announces 2020 Interim Results prnasia
August 26, 2020
For the current period, the Group recorded a revenue of RMB12,590 million, an increase of 12.6% year-on-year, and profit attributable to shareholders of RMB2,314 million, an increase of 23.2% year-on-year.
Therapix Biosciences Announces Interim Results of Phase IIa Study for Obstructive Sleep Apnea americanpharmaceuticalreview
June 20, 2019
Therapix Biosciences announced interim results from its Phase IIa clinical study at Assuta Medical Center in Israel, suggesting that THX-110, a combination of dronabinol (∆-9-tetrahydracannabinol) and CannAmide™ (palmitoylethanolamide, or PEA) ...
WuXi Biologics Reports Robust 2018 Interim Results en-cphi.cn
August 21, 2018
WuXi Biologics announced its unaudited interim results for the six months ended June 30, 2018 today.